First human test of new PET scan agent for solid tumors
Part of Cancer clinical trials.
This trial tests a new imaging agent called 68Ga-NI-FAPI to see how well it works in a PET scan for people with different types of solid tumors. The goal is to help doctors better see and understand tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that was confirmed by a biopsy or other tissue test.
- You are not pregnant or breastfeeding.
- You do not have severe liver or kidney problems.
- You are willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET/CT scan to see how a new imaging agent (18F-FAPIBiotin) spreads in the body and how much radiation it gives off. It's for people with confirmed solid tumors to help make future imaging more accurate.
This study tests how useful a special PET/CT scan (called 68Ga-FAPI) is for people who may have or have been diagnosed with cancer. The scan may help doctors see cancer activity more clearly.
This trial uses a special PET scan (68Ga-DOTA-NI-FAPI04) to get clearer images of various solid tumors. It may help doctors see your cancer better and plan your treatment.
This trial tests a new PET/CT scan that uses a special tracer (68Ga-FAPI-Biotin) to help detect and see various solid tumors. It may provide more detailed images to guide treatment decisions.
This study uses a new imaging agent called [68Ga]-FAPI-JNU to take detailed pictures of tumors with a PET/CT scan. It aims to see how well this tracer works in people with various types of cancer.
This study tests a new type of imaging scan called 68Ga-FAPI-PSMA PET that may help doctors better detect and diagnose solid tumors like prostate, liver, ovarian, or endometrial cancer. You would receive the scan before having a biopsy or surgery.
Hear when a new Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.